NCT01880697View on ClinicalTrials.gov

Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvanted Influenza Study Vaccine in Adults Aged 18 Years and Above

PHASE3CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Human Influenza
Interventions
BIOLOGICAL

TIVc

Trivalent Influenza Virus Vaccine (surface antigen, inactivated, cell-based)

Trial Locations (1)

18057

Rostock University, Department of Tropical Medicine and Infectious Diseases, Ernst Heydemann Strasse 6, Rostock

Sponsors

Lead Sponsor

Novartis Vaccines
All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY